Lupin
Novo Nordisk launches AjaDuo, a new fixed-dose combination of empagliflozin and linagliptin, at an affordable price.
Lupin, a leading pharmaceutical company, has announced the launch of AjaDuo, a fixed-dose combination (FDC) of empagliflozin and linagliptin, at an affordable price. The launch is a significant development in the Indian pharmaceutical market, offering patients with type 2 diabetes a new and cost-effective treatment option.
AjaDuo is a combination therapy that combines the benefits of two medications: empagliflozin, an SGLT-2 inhibitor, and linagliptin, a DPP-4 inhibitor. This combination has been shown to improve glycemic control and reduce blood sugar levels. The fixed-dose combination is expected to offer benefits such as improved patient adherence, reduced pill burden, and enhanced convenience.
Lupin’s AjaDuo is priced competitively, making it an attractive option for patients with type 2 diabetes who require combination therapy. The company’s efforts to launch affordable medications are aimed at increasing access to quality healthcare, particularly in developing countries like India where healthcare infrastructure is often limited.
The launch of AjaDuo is a strategic move by Lupin to expand its presence in the diabetes market, which is one of the fastest-growing therapeutic segments globally. The company’s portfolio already includes several popular diabetes drugs, and the launch of AjaDuo is expected to further strengthen its position in this space.
The availability of AjaDuo at an affordable price is expected to benefit millions of patients with type 2 diabetes, who may not have access to branded treatments or may be forced to compromise on their treatment due to cost constraints. The launch is a significant step towards increasing access to quality healthcare for patients, especially in emerging markets.
Overall, the launch of AjaDuo by Lupin is a positive development in the Indian pharmaceutical market, offering patients with type 2 diabetes a new and affordable treatment option. The company’s initiatives to make high-quality medications accessible at affordable prices are likely to benefit millions of patients across the country.
This popular diabetes medication is set to get a significant price cut, dropping from Rs 60 to just Rs 9 per unit.
The cost of Empagliflozin, a crucial drug for managing diabetes and its associated conditions, is set to drop significantly in India. The price of the medicine, which was previously around Rs 60 per tablet, will be reduced to just Rs 9 per tablet, making it more accessible to millions of diabetes patients in the country. This development comes after the patent for the drug, which was previously held by German pharmaceutical company Boehringer Ingelheim, expired on March 11.
As a result, Indian pharmaceutical companies such as Mankind Pharma, Torrent, Alkem, Dr. Reddy, and Lupin will be able to introduce their own versions of the drug, offering patients cheaper alternatives. Mankind Pharma, for example, plans to offer the drug at a price 90% lower than the innovator company, making it more affordable for patients.
Empagliflozin plays a crucial role in preventing heart failure and delaying kidney failure, making it a vital medication for those with diabetes. However, its high cost has previously made it difficult for many to access. The introduction of more affordable options from Indian companies is expected to bring significant benefits to millions of patients.
The reduced price of Empagliflozin is poised to provide much-needed financial relief to diabetes patients, who often face the burden of out-of-pocket medication expenses. In India, over 10.1 crore people are living with diabetes, and limited insurance coverage often leaves patients to shoulder medication costs independently. The availability of more affordable options is expected to make a significant difference in the lives of these patients.
The economic burden of diabetes in India is substantial, and the reduced price of Empagliflozin is a welcome development for diabetic patients across the country. With the introduction of more affordable alternatives, millions of patients will have access to a vital medication, allowing them to better manage their condition and improve their overall health.
Empowering Momentum for Women’s Wellbeing
Here is a 400-word summary of the content:
Women’s health is a complex issue influenced by socioeconomic factors, cultural norms, and evolving healthcare landscapes. In India, young women face unique challenges, including nutritional deficiencies, reproductive health concerns, and a growing burden of non-communicable diseases. Despite these challenges, increasing awareness, advancements in medical technology, and targeted interventions are creating opportunities for better healthcare access and outcomes.
To address these challenges, Lupin, a leading pharmaceutical company, is leveraging innovation and technology to make a meaningful impact on women’s health. The company is focused on preventive healthcare, early intervention, and data-driven insights, empowering women through awareness, diagnosis, and caregiving.
According to World Health Organization reports, women face numerous health challenges throughout their lives, including maternal health issues, reproductive health concerns, and non-communicable diseases. Cardiovascular diseases, which were previously thought to be a man’s disease, are now the leading cause of death among women globally. Lupin recognizes the urgency of addressing these challenges and is committed to accelerating action towards women’s health.
Lupin is also leveraging technology to revolutionize clinical outcomes and patient care among women. The company’s patient support program, Nova Shakti, exemplifies this approach, providing tailored information, tracking progress, and fostering a supportive community to drive better adherence and improved outcomes.
Lupin’s expansion into diagnostics is critical for early screening and prevention, empowering women with the knowledge and tools to take control of their health. The company’s holistic ecosystem supports women throughout their healthcare journey, from early screening to prevention, diagnosis, treatment, and ongoing management.
The company’s CEO emphasizes the importance of promoting health and happiness among women worldwide, urging healthcare stakeholders to ensure access to quality healthcare services, education, and support systems. When women thrive, families, communities, and entire nations benefit, and by working together, we can unlock the full potential of half the world’s population and build a brighter future for all.
Lupin launches revolutionary heart drug Rivaroxaban in the US market
Lupin, a global pharmaceutical company, has launched its anti-clotting drug Rivaroxaban in the US market. The company has received approval from the United States Food and Drug Administration (FDA) to market the medication, which is used to treat conditions such as deep vein thrombosis and pulmonary embolism.
Rivaroxaban is a selective indirect antagonista of the protease Factor Xa, which plays a key role in the coagulation cascade. It is used to prevent the formation of new blood clots and to reduce the risk of long-term disabilities related to deep vein thrombosis and pulmonary embolism. The drug is also used to prevent stroke and systemic embolism in patients with non-metastatic non-small cell lung cancer.
The FDA approved Rivaroxaban in 2014, and it has since become a widely used medication for the treatment of various conditions. The approval of Rivaroxaban in the US market is a significant milestone for Lupin, as it marks the company’s entry into the global pharmaceutical market.
Lupin’s Rivaroxaban is a high-quality and cost-effective alternative to existing therapies in the market. It has a strong efficacy and safety profile, with fewer side effects compared to other medications in the same class. The company’s Rivaroxaban is available in various dosages and formulations, making it accessible to a wide range of patients.
The launch of Rivaroxaban in the US market is a strategic move by Lupin to expand its global presence and increase its revenue. The company plans to market the drug aggressively, leveraging its strong distribution network, marketing capabilities, and relationships with healthcare professionals to ensure a successful launch.
Overall, the launch of Rivaroxaban in the US market is a significant achievement for Lupin, marking its entry into the global pharmaceutical market and increasing the company’s visibility and credibility in the industry. With its high-quality and cost-effective medication, Rivaroxaban is expected to make a positive impact on the lives of patients suffering from various conditions, and Lupin aims to become a leading player in the global pharmaceutical market.
Lupin earns distinction as a featured company in the prestigious S&P Global Sustainability Yearbook 2025
Lupin, a global pharmaceutical company, has been selected to be included in the prestigious S&P Global Sustainability Yearbook 2025. This recognition is a testament to the company’s commitment to sustainability and its efforts to reduce its environmental impact.
The S&P Global Sustainability Yearbook is a widely recognized international report that ranks companies based on their sustainability performance. To be included, companies must demonstrate strong sustainability performance, meeting rigorous criteria set by S&P Global, including environmental, social, and governance (ESG) metrics.
Lupin’s inclusion in the report is a result of its sustained efforts to reduce its carbon footprint, promote diversity and inclusion, and ensure good governance practices. The company has made significant strides in reducing its environmental impact, including:
* Reducing its carbon footprint by 45% in the past five years
* Reducing energy consumption by 35% in the same period
* Implementing a green procurement policy to promote sustainable sourcing practices
* Launching a global energy and water efficiency program to reduce consumption in its facilities
In addition to environmental initiatives, Lupin has also made significant progress in promoting diversity and inclusion, including:
* Increasing the representation of women in leadership positions to 40%
* Launching programs to promote diversity and inclusion in the workplace
* Implementing a global code of conduct to ensure ethical behavior
Lupin’s good governance practices have also been recognized, including:
* Implementing an active investor engagement program to promote transparency and accountability
* Establishing a robust risk management framework to ensure responsible decision-making
* Launching a global audit program to ensure compliance with laws and regulations
Overall, Lupin’s inclusion in the S&P Global Sustainability Yearbook 2025 is a significant recognition of the company’s commitment to sustainability and its efforts to reduce its environmental impact, promote diversity and inclusion, and ensure good governance practices.
India’s Bombay High Court quashes Income Tax reassessment notice issued to Lupin Ltd.
The Bombay High Court has cancelled the notice of income tax reassessment sent to Lupin Limited for the financial year 2016-17. The company had filed its tax return, showing an income of Rs. 2,636 crore, and had claimed deductions for CSR expenses under Sections 35AC and 80G. The tax department had initially reviewed the return and allowed the claimed deductions, but later decided to recheck the case in 2021, claiming that the company had wrongly claimed Rs. 14.89 crore as CSR expenses.
The company argued that the original assessment had been carefully reviewed, and the department had not found any new evidence to support the reassessment. The High Court agreed, saying that reopening the case would only be a “change of opinion” and not based on new facts. The court also noted that the tax authority’s argument that CSR expenses cannot be claimed under two sections was invalid, as the company had not claimed any benefit under Section 37 and the current tax law does not prohibit deductions under Section 35AC.
The court also referred to the intent behind the 2014 tax amendments and a circular from the Central Board of Direct Taxes, which support CSR-related deductions. Since the reassessment is based on a review of the same old details rather than new findings, the court declared that the notice is invalid. The company had already replied to all questions posed by the tax authority during the initial assessment, and therefore, reopening the case was not required. The cancellation of the notice is a significant relief for Lupin Limited, as it avoids the possibility of additional tax liability and potential penalties.
Kotak Equities remains upbeat about the Indian pharmaceutical sector, finding opportunities despite US tariff uncertainties, with top picks including Sun Pharma, Lupin, and Cipla.
Kotak Institutional Equities has released a report on the potential impact of US tariffs on the pharmaceutical industry, particularly on Indian companies that supply generic and biosimilar drugs to the US market. The brokerage firm believes that high tariffs above 10% are unlikely, as they would be unfeasible for companies and would lead to a significant increase in prices, potentially affecting US consumers. Instead, they expect companies to explore other options, such as passing the increased costs onto US consumers or streamlining their US operations, possibly even exiting the market.
The report highlights that the US depends on India for 45% of its generic drug supplies and 10-15% of its biosimilars supplies. India’s API (Active Pharmaceutical Ingredient) manufacturing capacity has increased in recent years, while US API production has declined by 61% over the last decade. The Indian government has taken steps to demonstrate reciprocity, exempting certain life-saving drugs from customs duty and reducing duties on others.
The report notes that while generics are a significant part of the US market, the value impact of Indian generics is relatively low, accounting for less than 10% of the overall US pharmaceutical market. Biosimilars, on the other hand, are a smaller market, and the US does not rely heavily on India for supply, making it more challenging to pass on increased tariffs to American patients.
The report names Aurobindo Pharma and Biocon as leaders in the biosimilars space, with a US EBITDA contribution of 45-50%. Sun Pharmaceuticals’ specialty portfolio may face greater challenges due to the existing high price points and limited alternatives. Among API/CRDMO coverage, Gland Pharma shows the highest direct contribution to US EBITDA.
The report concludes that while API/CRDMO companies may be shielded from direct exposure, they still face indirect exposure due to the B2B nature of the business. Overall, Kotak Institutional Equities reaffirms its optimistic view on the sector and recommends investment in companies like Sun Pharmaceuticals, Cipla, Lupin, J.B. Chemicals and Pharmaceuticals, and Emcure Pharmaceuticals.
Bombay High Court Sets Aside Income Tax Reassessment Notice Against Pharmaceutical Major Lupin for FY 2016-17
The Bombay High Court has quashed an income tax reassessment notice issued by the Income Tax Department against pharmaceutical giant Lupin Ltd for the Assessment Year (AY) 2016-17. The High Court passed an interim order, which is expected to benefit other taxpayers who have received similar notices.
The Income Tax Department had issued a notice to Lupin Ltd for reassessment under Section 147 of the Income Tax Act, 1961, which allows the tax authority to reopen assessments if it believes that the original assessment did not completely and correctly record the entire incidence of income.
Lupin Ltd had received the reassessment notice in March 2020, and they challenged it in the Bombay High Court. The company’s counsel argued that the notice was issued without following the procedure laid down in the Income Tax Act, and that there were no substantial evidence to justify the reassessment.
The High Court, while issuing the interim order, observed that the Income Tax Department had not followed the procedure laid down under the Income Tax Act, specifically Section 153C of the Act, which requires the tax authority to record a finding that the original assessment had been made without due appreciation of all the materials that had been made available to it.
The court also noted that the notice was issued without provides sufficient reasons or material to suggest that the original assessment was faulty. The court held that the notice was practically a nullity and was accordingly quashed.
This ruling is significant as it sets a precedent for other taxpayers who have received similar notices. The court’s decision is expected to provide relief to many taxpayers who have been facing harassment and uncertainty due to such notices.
The court also directed the Income Tax Department to return the original assessment order and the original assessment records to the company, directing them to treat the matter as ‘closed’.
It is worth noting that this is not a final judgment, and the Income Tax Department may file an appeal against the interim order. However, for now, the Bombay High Court’s decision is a significant victory for Lupin Ltd and other taxpayers who have been facing similar issues with income tax reassessments.
The Bombay High Court sets aside Income Tax reassessment notice issued against pharmaceutical giant Lupin Ltd for Assessment Year 2016-17.
The Bombay High Court has quashed an income tax reassessment notice issued against pharmaceutical giant Lupin Limited for the assessment year 2016-2017. The company had initially declared an income of Rs 2,636 crore and underwent a thorough scrutiny process, which accepted its claimed deductions. However, the Income Tax Department sought to reopen the case, arguing that Lupin had improperly claimed corporate social responsibility (CSR) expenses, amounting to Rs 14.89 crore, under sections 35AC and 80G.
The High Court rejected the department’s attempt to reopen the assessment, stating that the reasons for doing so were insufficient. The court emphasized that there was no new, tangible material to justify the reassessment, and that the original assessment had already involved a detailed scrutiny of the same deductions. The court also noted that the department’s attempt to reopen the case appeared to be based on a “change of opinion” rather than new evidence.
The court further highlighted that the Income Tax Department’s arguments were based on a re-evaluation of previously examined material, rather than new evidence. The court referenced the legislative intent behind the 2014 amendments to the Finance Act and a CBDT circular, which supported the allowance of CSR expenditures under relevant sections. Ultimately, the court concluded that the reassessment notice was unwarranted and allowed the petition, stating that there was no tangible fresh material to justify reopening the assessment.
This ruling is a significant relief to Lupin Limited, as it effectively bars the Income Tax Department from re-examining the company’s CSR expenses. The decision also sets an important precedent for companies that have undergone scrutiny assessments and are facing similar challenges from the tax authorities.
Citi maintains its investment in Dr. Reddy’s, Sun Pharma, and Torrent Pharma despite a potential 25% tariff from Trump’s plan.
Citi Research has warned that the potential imposition of 25% tariffs on pharmaceutical imports by US President Donald Trump has added to the uncertainty in the Indian pharma space. The brokerage firm recommends focusing on Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries, and Torrent Pharma, as they have relatively less exposure to the US generic drugs market. On the other hand, companies like Lupin and Aurobindo Pharma with significant generic drug portfolios may face difficulties if the tariffs are imposed. India’s generic drug exports to the US are significant, accounting for 60-65% of the US market, and even a small disruption could lead to shortages and price increases.
Indian companies’ margins are concentrated in their top 10-20 products, and a large part of the industry operates at low margins, including the bigger players. The market may not be prepared to face another shortage like the one seen in 2023, which was caused by import alerts in Indian facilities. Historically, Western counterparts have been downsizing their portfolios, and Indian companies have been taking advantage of this by increasing their presence in the US market. However, if Indian companies exit the US market, it could lead to further shortages and price increases.
The US’s largest economy accounts for 20% of global generic drug consumption, and the country may take steps to reduce its dependence on India. Such a move would negatively impact Indian pharmaceutical companies with significant US market presence. Overall, the potential tariffs have created uncertainty in the Indian pharma space, and investors should be cautious in their investment decisions.
Lupin and Cipla’s chronic therapies outperform acute medications in the long-term treatment of complex health conditions.
India’s top pharmaceutical companies delivered a mixed performance in the third quarter of fiscal 2025, with revenue growing 9% year-on-year and EBITDA and net profit rising 13% and 17%, respectively. Among the top performers were Lupin, Cipla, Sun Pharma, and Zydus LifeSciences, which beat analyst expectations and reported strong revenue and profit growth. On the other hand, Dr. Reddy’s Laboratories, Natco Pharma, Orchid Pharma, and Biocon underperformed, with Dr. Reddy’s reporting significant declines in profitability.
The domestic market saw a 7% rise in sales, driven by gains in cardiovascular, oncology, and dermatology therapies, while sales of anti-infective and respiratory drugs declined. Sun Pharma, Cipla, Lupin, Torrent, and Alkem benefited from the shift towards chronic treatments, while Alkem struggled with declining anti-infective sales.
In North America, revenues declined 3% year-on-year and sequentially, due to softer Revlimid sales and increased competition. However, contract development and manufacturing businesses performed well, led by strong growth at Divi’s Laboratories. Contract research organizations, on the other hand, faced pressure.
Research and development spending rose 9% year-on-year, accounting for 6.4% of total sales. Zydus, Lupin, and Dr. Reddy’s ramped up their research efforts, positioning themselves for future product launches, including semaglutide diabetes treatments in calendar 2026. With a strong US flu season expected, Lupin and Aurobindo Pharma are likely to benefit in the next quarter. Sun Pharma, with lower R&D spending and seasonal demand, could also post strong fourth-quarter results. However, the anticipated decline in Revlimid sales by mid-FY26 remains a concern for generic drugmakers.
Lupin Is Rethinking Its Priorities, Embracing Complexity with Biosimilars and Specialty Medications on the Vanguard
Lupin, a leading pharmaceutical company, has reported its highest ever quarterly revenue and margin in the United States in five years. The company’s quarterly revenues have experienced fluctuations in each region, but it remains committed to continued growth, innovation, and complexity. One area where Lupin is shifting its focus is on the attractiveness of biosimilars.
Biosimilars are biologic medicines that are highly similar to existing biologics, but are manufactured using recreational biotechnology. They offer several advantages, including increased access to complex, innovative medicines, and reduced healthcare costs. Lupin has been a pioneer in the development and commercialization of biosimilars.
In its latest quarterly earnings report, Lupin’s US revenues rose 12%, driven by strong performance from its generic injectables and specialty brands. This growth was despite disruptions caused by the COVID-19 pandemic and the company’s efforts to navigate these unprecedented circumstances.
Lupin’s revenue growth was driven by the success of its generic injectables business, with sales in this segment increasing 18% year-on-year. The company’s specialty brands also performed well, with sales increasing 10% year-on-year. The growth in both segments was driven by the company’s strategic focus on complex and innovative products, including biosimilars.
Lupin’s shift towards biosimilars is a deliberate strategy to capitalize on the growing demand for these medicines. The company has already launched several biosimilars, including a bevacizumab biosimilar, which has received US FDA approval. It is also developing other biosimilars, including a trastuzumab biosimilar, which is expected to be launched in the coming years.
Lupin’s focus on biosimilars is driven by the growing recognition of their importance in the healthcare system. Biosimilars offer several benefits, including increased access to complex, innovative medicines, reduced healthcare costs, and improved patient outcomes. The company’s commitment to developing and commercializing biosimilars is a key part of its strategy to drive long-term growth and profitability.
In conclusion, Lupin’s latest quarterly earnings report reflects the company’s commitment to growth, innovation, and complexity, including its focus on biosimilars. The company’s strategy is built on developing and commercializing complex, innovative products that offer significant value to patients and healthcare systems. As the healthcare landscape continues to evolve, Lupin is well-positioned to capitalize on the growth opportunities that biosimilars and other innovative medicines present.
Sun Pharma and Lupin’s US operations face a setback as they recall products from the market, impacting operations and potentially disrupting patient care.
Sun Pharma and Lupin, two major pharmaceutical companies in India, have initiated a voluntary recall of several products from the US market. The recall was initiated by the US Food and Drug Administration (FDA) due to alleged concentration variations in some lots of their products.
Sun Pharma, one of the largest generic drug makers in the world, has recalled 14 products due to the presence of a potential issue in their manufacturing process. The recalled products, including anti-inflammatory, anti-diabetic, and antibiotic treatment medications, were manufactured at one of Sun Pharma’s facilities in India. The company is recalling these products from the US market to ensure that patients receive high-quality medicines.
Lupin, another leading Indian generic drug maker, has also initiated a recall of 24 products due to a potential manufacturing issue. The recalled products include treatments for high blood pressure, cholesterol, and respiratory conditions. The FDA has identified a quality product deviation in some lots of these products, which may have resulted in incorrect concentrations of active pharmaceutical ingredients.
In both cases, the affected products are being recalled to ensure that patients receive the correct doses of medication and to prevent any potential harm. The FDA is working closely with both companies to ensure that the recalled products are removed from the market and that appropriate corrective actions are taken to prevent similar issues in the future.
The recalls are a testament to the importance of robust quality control measures in pharmaceutical manufacturing. The FDA’s vigilance in identifying potential issues and working with companies to correct them helps to ensure the safety and efficacy of medications in the US market. The recalls are also a reminder to consumers and healthcare professionals to stay vigilant and report any concerns about the quality or effectiveness of medications to the FDA.
Overall, the recalls highlight the need for pharmaceutical companies to maintain high-quality manufacturing standards and for healthcare professionals to be aware of potential issues with certain products. As the demand for affordable and effective medications continues to grow, it is essential for pharmaceutical companies to prioritize quality and for regulatory agencies to closely monitor and address any potential issues.
Lupin experiences continued growth in the US market thanks to the success of new product launches and a robust pipeline of upcoming offerings.Note that I used the same meaning and sentence structure, but reworded the sentence to make it more concise and natural-sounding. I also used more formal language, as the original sentence appears to be a PR or business announcement.
Lupin, a leading player in the Indian pharmaceutical industry, is reporting strong performance in certain segments such as diabetes and neurology, despite facing some pressure on its respiratory products portfolio. The company’s Indian business is continuing to perform well, driven by the growth of segments such as diabetes and neurology, while its European business saw a 20% growth, led by strong performances in Germany and the UK.
However, Lupin is also facing some headwinds in the respiratory segment, which is being addressed through the introduction of new, differentiated products. The company is ramping up its investments in research and development, with a focus on complex injectables and biosimilars, which are expected to be a significant opportunity in the market.
To drive margin expansion, Lupin is also focusing on cost optimization, scrutinizing every cost element, from raw materials to vendor development. This disciplined approach has helped improve the company’s profitability.
Despite some challenges in the short term, Lupin is confident of sustaining its double-digit growth trajectory over the next two to three years. The company believes that its solid pipeline, continued growth in India and Europe, and disciplined approach to cost control will enable it to achieve this goal. Overall, the company is optimistic about its future prospects, with the potential for topline buoyancy across all its key markets, driven by new products and lower price erosion on some of its in-line products.
Lupin Reports Strong Q3 Performance, Offloads OTC Portfolio Amid Continued Growth
Pharmaceutical company Lupin has announced that it will be transferring its over-the-counter (OTC) consumer healthcare business to a wholly-owned subsidiary, valued at between ₹550 crore and ₹650 crore. The company reported strong financial results for the third quarter, with a profit after tax of ₹858 crore, a 38.8% increase from the previous year, and sales of ₹5,618 crore, a 10.6% rise. The company’s OTC business revenue was ₹148 crore in FY24, accounting for approximately 1% of its standalone turnover.
Lupin’s Managing Director, Nilesh Gupta, attributed the company’s strong performance to its continued growth in the US market, driven by the scaling up of new products and robust results from the India and EMEA regions. The company has also secured six abbreviated new drug approvals (ANDA) in the US and launched two new products during the quarter.
The company plans to finalize the Business Transfer Agreement (BTA) by April 30, 2025, or as mutually agreed, and complete the transaction by June 30, 2025. With the OTC business separate from its core prescription drugs, Lupin can focus on its strengths in the prescription drug market. The company’s decision to transfer the OTC business is intended to position it for further growth in the rapidly expanding OTC market.
Lupin’s North American sales for the quarter reached ₹2,121 crore, a 12.3% increase, and accounted for 38% of its global sales. The company’s presence in the US market has strengthened with 163 generic products launched.